Northwest Biotherapeutics (NWBO) Debt Ratio (2010 - 2026)

Northwest Biotherapeutics' Debt Ratio history runs 17 years deep, the most recent figure standing at 0.09 for Q1 2026.

• On a quarterly basis, Debt Ratio fell 85.04% year-over-year to 0.09 in Q1 2026; TTM through Mar 2026 was 0.09, a 85.04% decrease from a year earlier, with the FY2025 full-year figure at 0.27, down 67.46% from the prior year.
• Debt Ratio slipped to 0.09 in Q1 2026 per NWBO's latest filing, from 0.27 in the prior quarter.
• Across five years, Debt Ratio topped out at 1.06 in Q4 2023 and bottomed at 0.09 in Q1 2026.
• The 5-year median for Debt Ratio is 0.68 (2024), against an average of 0.68.
• Across the five-year window, Debt Ratio jumped 126.22% in 2023 and slumped 85.04% in 2026, its largest moves.
• Year by year, Debt Ratio stood at 0.47 in 2022, then soared by 126.22% to 1.06 in 2023, then retreated by 22.34% to 0.82 in 2024, then tumbled by 67.46% to 0.27 in 2025, then plunged by 66.36% to 0.09 in 2026.
• Per Business Quant, the three latest NWBO Debt Ratio figures stand at 0.09 (Q1 2026), 0.27 (Q4 2025), and 0.55 (Q3 2025).